• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)

    11/22/23 4:31:25 PM ET
    $GRAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRAY alert in real time by email
    SC 13D/A 1 d529649dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    CALCIMEDICA, INC.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    38942Q 202

    (CUSIP Number)

    Valence Investments SPV IV, LLC

    Valence Investments SPV V, LLC

    Valence Investments SPV VI, LLC

    Eric Roberts

    Rachel Leheny

    590 Madison Avenue, 21st Floor

    New York, NY 10022

    (212) 521-4379

    with copy to:

    Evan Ng

    Dorsey & Whitney LLP

    167 Hamilton Avenue, Suite 200

    Palo Alto, CA 94301

    (650) 565-2252

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 7, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 38942Q 202    SCHEDULE 13D    Page 2 of 9

     

      1   

    NAMES OF REPORTING PERSON: Valence Investments SPV IV, LLC

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY):

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY:

     

        

      4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

     

    OO

      5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):  ☐

     

        

      6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

          7     

    SOLE VOTING POWER:

     

    0

          8     

    SHARED VOTING POWER:

     

    356,989 (See Item 5)

          9     

    SOLE DISPOSITIVE POWER:

     

    0

        10     

    SHARED DISPOSITIVE POWER:

     

    356,989 (See Item 5)

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    356,989 (See Item 5)

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):  ☐

     

    Not Applicable

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

     

    6.3%1

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    PN

      

     

    1 

    The calculation of percentage ownership is based on a total of 5,684,873 shares of common stock outstanding of the Issuer as set forth In the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 9, 2023.


    CUSIP No. 38942Q 202    SCHEDULE 13D    Page 3 of 9

     

     

      1   

    NAMES OF REPORTING PERSON: Valence Investments SPV V, LLC

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY):

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY:

     

        

      4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

     

    OO

      5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):  ☐

     

        

      6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

          7     

    SOLE VOTING POWER:

     

    0

          8     

    SHARED VOTING POWER:

     

    86,0982 (See Item 5)

          9     

    SOLE DISPOSITIVE POWER:

     

    0

        10     

    SHARED DISPOSITIVE POWER:

     

    86,0982 (See Item 5)

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    86,0982 (See Item 5)

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):  ☐

     

        

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

     

    1.5%3

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    PN

     

     

    2 

    Includes 66,228 shares of common stock and 19,870 immediately exercisable warrants to purchase common stock at an exercise price of $27.94 per share received pursuant to the Merger Agreement.

    3 

    The calculation of percentage ownership is based on a total of 5,684,873 shares of common stock outstanding of the Issuer as set forth In the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 9, 2023.


    CUSIP No. 38942Q 202    SCHEDULE 13D    Page 4 of 9

     

      1   

    NAMES OF REPORTING PERSON: Valence Investments SPV VI, LLC

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY):                                         

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY:

     

        

      4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

     

        OO

      5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):  ☐

     

        

      6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

          7     

    SOLE VOTING POWER:

     

    0

          8     

    SHARED VOTING POWER:

     

    316,109 (See Item 5)

          9     

    SOLE DISPOSITIVE POWER:

     

    0

        10     

    SHARED DISPOSITIVE POWER:

     

    316,109 (See Item 5)

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    316,109 (See Item 5)

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):  ☐

     

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

     

    5.6%4

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    PN

     

    4 

    The calculation of percentage ownership is based on a total of 5,684,873 shares of common stock outstanding of the Issuer as set forth In the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 9, 2023.


    CUSIP No. 38942Q 202    SCHEDULE 13D    Page 5 of 9

     

      1   

    NAMES OF REPORTING PERSON: Eric W. Roberts

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY):

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY:

     

        

      4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

     

    PF

      5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):  ☐

     

        

      6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    United States

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

          7     

    SOLE VOTING POWER:

     

    187,1845

          8     

    SHARED VOTING POWER:

     

    759,1966 (See Item 5)

          9     

    SOLE DISPOSITIVE POWER:

     

    187,1845

        10     

    SHARED DISPOSITIVE POWER:

     

    759,1966 (See Item 5)

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    946,3805,6 (See Item 5)

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):  ☐

     

        

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

     

    16.3%7

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    IN

     

    5 

    Includes 20,287 shares of common stock held directly by Mr. Roberts, 51,778 shares of common stock held in individual retirement accounts for the benefit of Mr. Roberts, 113,115 Employee Stock Options to purchase common stock at an exercise price ranging from $3.25 to $17.34, and 2,004 warrants to purchase common stock at an exercise price of $10.42 per share.

    6 

    Includes 19,870 warrants to purchase common stock at an exercise price of $27.94 held by Valence Investments SPV V, LLC, 356,989 shares of common stock held by Valence Investments SPV IV, LLC, 66,228 shares of common stock held by Valence Investments SPV V, LLC, and 316,109 shares of common stock held by Valence Investments SPV VI, LLC. Mr. Roberts is a co-founder and managing director of Valence Investments SPV IV, LLC, Valence Investments SPV V, LLC, and Valence Investments SPV VI, LLC.

    7 

    The calculation of percentage ownership is based on a total of 5,684,873 shares of common stock outstanding of the Issuer as set forth In the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 9, 2023.


    CUSIP No. 38942Q 202    SCHEDULE 13D    Page 6 of 9

     

      1   

    NAMES OF REPORTING PERSON: A. Rachel Leheny

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY):

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY:

     

        

      4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

     

    PF

      5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):  ☐

     

        

      6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    United States

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

          7     

    SOLE VOTING POWER:

     

    209,7288

          8     

    SHARED VOTING POWER:

     

    759,1969(See Item 5)

          9     

    SOLE DISPOSITIVE POWER:

     

    209,7288

        10     

    SHARED DISPOSITIVE POWER:

     

    759,1969 (See Item 5)

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    968,9248,9 (See Item 5)

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):  ☐

     

        

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

     

    16.4%10

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    IN

     

     

    8 

    Includes 18,840 shares of common stock held directly by Ms. Leheny, 1,000 shares of common stock held by Ms. Leheny’s spouse, and 189,888 Employee Stock Options to purchase common stock at an exercise price ranging from $2.44 to $17.34.

    9 

    Includes 19,870 warrants to purchase common stock at an exercise price of $27.94 held by Valence Investments SPV V, LLC, 356,989 shares of common stock held by Valence Investments SPV IV, LLC, 66,228 shares of common stock held by Valence Investments SPV V, LLC, and 316,109 shares of common stock held by Valence Investments SPV VI, LLC. Ms. Leheny is a co-founder and managing director of Valence Investments SPV IV, LLC, Valence Investments SPV V, LLC, and Valence Investments SPV VI, LLC.

    10 

    The calculation of percentage ownership is based on a total of 5,684,873 shares of common stock outstanding of the Issuer as set forth In the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 9, 2023.


    CUSIP No. 38942Q 202    SCHEDULE 13D    Page 7 of 9

     

    Reference is hereby made to the statements on Schedule 13D originally filed with the Securities and Exchange Commission on March 30, 2023 (the “Schedule 13D”) which is incorporated by reference.

    This Amendment No. 1 to the Schedule 13D filed, relating to the common stock, par value $0.0001 per share (the “Common Stock”) of CalciMedica, Inc., a Delaware corporation (the “Issuer”) amends and supplements certain of the items set forth therein.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended supplemented by adding the following at the end of Item 3:

    Stock-Based Compensation

    Mr. Roberts and Ms. Leheny also receive, from time to time, equity-based awards as part of their compensation for their services as employees of the Issuer.

    Open-Market Purchases

    From time to time, Mr. Roberts and Ms. Leheny make purchases of Common Stock in the open market using their personal funds. Such transactions are described in greater detail in Item 5 below.


    CUSIP No. 38942Q 202    SCHEDULE 13D    Page 8 of 9

     

    Item 5. Interest in Securities of the Issuer.

    Item 5 is hereby amended and supplemented as follows:

    The Reporting Persons effected the following transactions in the Common Stock on the dates indicated, and such transactions are the only transactions in the Common Stock by the Reporting Persons in the sixty days preceding the filing of this Amendment, or since the last 13D filing, whichever is less:

     


    Name

      

    Nature of
    Transaction

       Date      Number of
    Shares of
    Common
    Stock
         Weighted
    Average
    Price Per
    Share
         Range of
    Prices
     

    Leheny

       Open Market Purchase      5/16/2023        1,000      $ 2.69      $ 2.69  

    Roberts

       Open Market Purchase      5/16/2023        3,500      $ 2.71      $ 2.65 -$2.75  

    Roberts

       Open Market Purchase      5/17/2023        3,000      $ 2.68      $ 2.68  

    Roberts

       Open Market Purchase      5/16/2023        1,800      $ 2.72      $ 2.60 - $2.76  

    Roberts

       Open Market Purchase      5/22/2023        6,000      $ 2.95      $ 2.95  

    Roberts

       Open Market Purchase      5/23/2023        2,000      $ 3.26      $ 3.25 - $3.276  

    Leheny

       Open Market Purchase      5/23/2023        3,000      $ 3.34      $ 3.09 - $3.37  

    Roberts

       Open Market Purchase      5/30/2023        2,000      $ 3.86      $ 3.86  

    Leheny

       Open Market Purchase      5/31/2023        1,000      $ 4.21      $ 4.00 - $4.48  

    Roberts

       Open Market Purchase      6/1/2023        2,000      $ 4.42      $ 4.37 - $4.43  

    Roberts

       Open Market Purchase      6/2/2023        1,687      $ 4.90      $ 4.97628 -$4.90  

    Leheny

       Open Market Purchase      5/16/2023        1,000      $ 2.70      $ 2.68 - $2.70  

    Leheny

       Open Market Purchase      6/2/2023        1,000      $ 4.80      $ 4.80  

    Leheny

       Open Market Purchase      6/6/2023        1,000      $ 5.13      $ 4.48 - $5.24  

    Leheny

       Open Market Purchase      6/7/2023        1,000      $ 5.25      $ 5.225 - $5.25  

    Roberts

       Open Market Purchase      6/6/2023        3,200      $ 5.09      $ 5.09  

    Roberts

       Open Market Purchase      6/7/2023        1,500      $ 5.23      $ 5.20 - $5.25  

    Leheny

       Open Market Purchase      6/8/2023        1,000      $ 5.23      $ 5.20 - $5.25  

    Leheny

       Open Market Purchase      6/9/2023        400      $ 5.25      $ 5.25  

    Roberts

       Open Market Purchase      6/8/2023        485      $ 5.20      $ 5.20  

    Roberts

       Open Market Purchase      6/20/2023        500      $ 4.85      $ 4.85  

    Roberts

       Open Market Purchase      6/21/2023        2,000      $ 4.13      $ 3.95 - $4.35  

    Roberts

       Open Market Purchase      6/23/2023        500      $ 3.35      $ 3.35  

    Roberts

       Open Market Purchase      6/26/2023        200      $ 3.53      $ 3.53  

    Roberts

       Open Market Purchase      6/26/2023        1,200      $ 3.70      $ 3.53 - $3.7483  

    Roberts

       Open Market Purchase      8/21/2023        1,750      $ 3.25      $ 3.20 - $3.30  

    Roberts

       Open Market Purchase      8/22/2023        714      $ 3.27      $ 3.12 - $3.35  

    Roberts

       Open Market Purchase      8/25/2023        736      $ 3.18      $ 3.18  

    Roberts

       Open Market Purchase      8/29/2023        223      $ 3.02      $ 3.02  

    Leheny

       Open Market Purchase      11/3/2023        5,000      $ 2.85      $ 2.85  

    Roberts

       Open Market Purchase      11/3/2023        3,200      $ 2.80      $ 2.795672 -$2.80  

    Roberts

       Open Market Purchase      11/3/2023        5,860      $ 2.70      $ 2.60 - $2.79496  


    CUSIP No. 38942Q 202    SCHEDULE 13D    Page 9 of 9

     

    Signatures

    After reasonable inquiry and to the best knowledge and belief of the undersigned, such person certifies that the information set forth in this Statement with respect to such person is true, complete and correct.

     

        VALENCE INVESTMENTS SPV IV, LLC
    Dated: November 22, 2023     By:   /s/ Eric Roberts
        Name:   Eric Roberts
        Title:   Manager

     

       

    VALENCE INVESTMENTS SPV V, LLC

    Dated: November 22, 2023     By:   /s/ Eric Roberts
        Name:   Eric Roberts
        Title:   Manager

     

        VALENCE INVESTMENTS SPV VI, LLC
    Dated: November 22, 2023     By:   /s/ Eric Roberts
        Name:   Eric Roberts
        Title:   Manager
        ERIC ROBERTS:
    Dated: November 22, 2023     /s/ Eric Roberts
        A. RACHEL LEHENY:
    Dated: November 22, 2023     /s/ A. Rachel Leheny
    Get the next $GRAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRAY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GRAY
    Financials

    Live finance-specific insights

    See more
    • Graybug and CalciMedica Enter into Definitive Merger Agreement

      – Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joint webcast on November 22, 2022, at 8:00 a.m. Eastern Time REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) and CalciMedi

      11/21/22 6:52:03 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

      REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) ("Graybug" or the "Company"), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the same period in 2021. Research and development expense for the quarter ended September 30, 2022 was $3.2 million compared to $4.0 million for the same period in 2021. The decrease was primarily due

      11/10/22 4:58:58 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments

      BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022. Recent Corporate Developments Announced review of strategic alternatives — On June 28, 2022, Graybug announced that its Board of Directors would conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. Alternatives being explored include the potential for an acquisition, company sale, merger, d

      8/11/22 7:30:00 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)

      SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)

      2/8/24 5:55:57 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Graybug Vision Inc. (Amendment)

      SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

      2/8/24 10:08:18 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Graybug Vision Inc. (Amendment)

      SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

      2/7/24 11:14:29 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    SEC Filings

    See more
    • Graybug Vision Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - CalciMedica, Inc. (0001534133) (Filer)

      2/13/24 5:30:00 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Graybug Vision Inc.

      EFFECT - CalciMedica, Inc. (0001534133) (Filer)

      2/12/24 12:15:11 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Graybug Vision Inc.

      S-3 - CalciMedica, Inc. (0001534133) (Filer)

      1/31/24 5:12:29 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sanderling Venture Partners Vi Lp bought $2,515,080 worth of shares (679,384 units at $3.70), increasing direct ownership by 35% to 946,744 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      1/25/24 8:00:32 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Middleton Fred A bought $2,515,080 worth of shares (679,384 units at $3.70) (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      1/25/24 8:00:34 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wilson Robert N bought $1,670 worth of shares (506 units at $3.30), increasing direct ownership by 0.28% to 182,161 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      12/13/23 8:45:28 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Roberts Eric W was granted 91,086 shares, increasing direct ownership by 449% to 111,373 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      2/6/24 5:34:17 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanderling Venture Partners Vi Lp bought $2,515,080 worth of shares (679,384 units at $3.70), increasing direct ownership by 35% to 946,744 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      1/25/24 8:00:32 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Middleton Fred A bought $2,515,080 worth of shares (679,384 units at $3.70) (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      1/25/24 8:00:34 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Graybug Vision downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Graybug Vision from Outperform to Market Perform and set a new price target of $5.00 from $23.00 previously

      5/13/21 7:17:20 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Vision downgraded by Needham

      Needham downgraded Graybug Vision from Buy to Hold

      5/13/21 6:13:16 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Graybug Vision with a new price target

      SVB Leerink reiterated coverage of Graybug Vision with a rating of Outperform and set a new price target of $23.00 from $45.00 previously

      3/15/21 8:09:07 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Vision Appoints Dirk Sauer to Board of Directors

      BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Directors, effective April 13, 2022. Dr. Sauer will serve as a member of the Nomination and Corporate Governance Committee of the Board. He will also chair the Science and Innovation Committee, the purpose of which is to advise the Board on the company's research and development as well as clinical manufacturing and control strategies. Dr. Sauer succeeds Gerald Cagle, PhD, who is retiring from the Graybug Bo

      4/13/22 4:05:00 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team

      REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment of Bettina Maunz as Chief People Officer. In addition to building and leading the human resources function for Graybug Vision, Ms. Maunz will serve as Head of Communications and be a member of the company’s executive team. “We are delighted for Bettina to join Graybug as Chief People Officer. Her leadership, culture and communications experience will be important assets to our team,” said Frederic Guera

      2/1/21 7:30:00 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Announces Name and Trading Symbol Change

      REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its trading symbol to "CALC." The Company's common stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol "CALC." The name and trading symbol change were undertaken in connection with the previously announced merger between Graybug and CalciMedica, Inc. (CalciMedica). About GraybugGraybug is a clinical-stage biopharmaceutical company focused on developing transform

      3/20/23 1:22:24 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug and CalciMedica Enter into Definitive Merger Agreement

      – Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joint webcast on November 22, 2022, at 8:00 a.m. Eastern Time REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) and CalciMedi

      11/21/22 6:52:03 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care